Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?-Reference-Cited by-同舟云学术

Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?

Published:2012-09-19 Issue:6 Volume:14 Page:684-691
ISSN:1523-3782
Container-title:Current Cardiology Reports
language:en
Short-container-title:Curr Cardiol Rep

Author:

Larach Daniel B.,deGoma Emil M.,Rader Daniel J.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11886-012-0317-3.pdf

Reference86 articles.

1. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–16.

2. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.

3. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51:2199–211.

4. •• Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. AIM-HIGH trial stopped early due to futility: niacin increased HDL-C but did not decrease CV events.

5. Roche provides update on Phase III study of dalcetrapib. Roche. 2012. http://www.roche.com/media/media_releases/med-cor-2012-05-07.htm . Accessed 11 Sept 2012.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A decreased level of high‐density lipoprotein is a possible risk factor for type 2 diabetes mellitus: A review;Health Science Reports;2023-12

2. The determinants of collateral circulation status in patients with chronic cerebral arterial circle occlusion: A STROBE Study;Medicine;2022-06-30

3. CRISPR/dCas9 Transcriptional Activation of Endogenous Apolipoprotein AI and Paraoxonase 1 in Enterocytes Alleviates Endothelial Cell Dysfunction;Biomolecules;2021-11-25

4. Clusterin, paraoxonase 1, and myeloperoxidase alterations induce high‐density lipoproteins dysfunction and contribute to peripheral artery disease; aggravation by type 2 diabetes mellitus;BioFactors;2021-11-06

5. GINKGOLIDE B EXERTS ANTI-DIABETIC ATHEROSCLEROSIS THROUGH PPARG SIGNALING PATHWAY;ACTA MEDICA MEDITERR;2021